ClinicalTrials.gg
RecruitingNCT06830031C402Updated Sep 11, 2026

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

A Phase 1 interventional study of C402-CD19-CAR in Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes and Follicular Lymphoma Grade 3B, sponsored by Shanghai Exuma Biotechnology Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Shanghai Exuma Biotechnology Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Planned enrollment
203rd of 273
18 · median 30
Started
2025
with 40 others
Phase 1
124 of 283
57 open now
Primary completion
2029-04
later than 131 of 145 live
Registered
219th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 203rd largest by planned enrollment of the 273 interventional ones that give a count, is one of 41 that started in 2025, is one of 124 in phase 1, reaches primary completion later than 131 of the 145 other live ones, and was the 219th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the recommended Phase 2 dose of C402-CD19-CAR.

Read the detailed description

This is a single-arm, open-label, phase 1 clinical study of C402-CD19-CAR cell therapy, to evaluate the safety, tolerability, efficacy of C402-CD19-CAR in subject with relapsed or refractory large B cell lymphoma.

Subjects that meet inclusion criteria with positive CD19 (IHC ≥50% tumor cells or FACS ≥70% tumor cells) will receive C402-CD19-CAR treatment according to the modified 2+3+3 dose escalation design.

03

Conditions studied

  • Diffuse Large B-cell-lymphoma
  • DLBCL, Nos Genetic Subtypes
  • Follicular Lymphoma Grade 3B
  • PMBL
  • HGBL With MYC and BCL2 and/or BCL6 Rearrangements
  • HGBL, Nos

Browse trials for

Keywords

  • autologous fast CAR-T
  • CD19
  • B cell lymphoma
  • subcutaneous injection
  • without lymphodepletion
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Must meet all the following inclusion criteria:

  1. Male or female 18-75 years (inclusive);
  2. Patients can understand this study and capable of providing ;
  3. Patients with willingness to be in the study and comply with the study visit procedures and other protocol requirements;
  4. Diagnosed with CD19-positive large B-cell lymphoma (LBCL) based on cytology or histology according to the WHO 2016 standards, including diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), grade 3b follicular lymphoma (FL), transformed diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), high-grade B-cell lymphoma (HGBL) with MYC, BCL-2, and/or BCL-6 rearrangements, and high-grade B-cell lymphoma not otherwise specified (HGBL-NOS). For CD19 expression status, subjects with a clear past record of tumor histological diagnosis as CD19-positive (within 6 months prior to screening with no CD19-related treatment in the last 6 months) and tumors showing CD19-positive lymphoma levels ≥ 50% by IHC or CD19-positive lymphoma levels ≥ 70% by flow cytometry. If there is no previous CD19 tumor testing or the result is over 6 months prior to screening, a new tumor pathology sample must be provided or re-collected for CD19-positive diagnosis by the institution, with IHC showing CD19-positive lymphoma levels ≥ 50% or flow cytometry showing CD19-positive lymphoma levels ≥ 70%.
  5. For or relapsed large B-cell lymphoma subjects, must have received at least anthracycline-based therapy and rituximab (or other CD20-targeted drugs, excluding CD20-negative cases). If previously treated with R-CHOP or other CD20-targeted therapy, the best treatment outcome prior to relapse must have been complete remission (CR). Subjects should meet the criteria for relapse, progression, or failure after therapy; or relapse after hematopoietic stem cell transplantation (auto-HSCT). If the subject has undergone previous auto-HSCT, the best treatment outcome prior to relapse must have been CR, and the relapse should occur more than 12 months after the previous treatment. (Refractory is defined as the best response to the most recent treatment being disease progression or stable disease after at least 2 cycles of the last-line therapy).
  6. According to the 2014 Lugano Treatment Response Assessment Criteria, at least one measurable tumor lesion should be present (lesions can be measured with PET results; lymph node lesions [long axis LDi > 15mm] or extra nodal lesions [long axis LDi > 10mm]);
  7. Expected survival time greater than 12 weeks;
  8. score of 0-1;
  9. Able to establish an intravenous route for PBMC collection, meeting the following hematologic parameters before screening: ≥ 80 g/L, ≥ 1.0 × 10\^9/L, count ≥ 75 × 10\^9/L, lymphocyte count ≥ 0.5 × 10\^9/L (if using bone marrow stimulants or blood transfusion, a of 7 days is required; for granulocyte colony-stimulating factor [G-CSF] or granulocyte-macrophage colony-stimulating factor [GM-CSF], a washout period of 4 weeks or 5 half-lives is required);
  10. Liver and kidney function, as well as heart and lung function, should meet the following requirements:

    1. Serum creatinine ≤ 1.5 × or ≥ 50 mL/min (using the Cockcroft-Gault formula);
    2. ≥ 50%, with no pericardial effusion or pleural effusion detected;
    3. Oxygen saturation ≥ 92% without oxygen support;
    4. Total ≤ 1.5 × ULN (for patients with Gilbert's syndrome or lymphoma involving the liver, ≤ 3 × ULN);
    5. (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN;
    6. Fibrinogen ≥ 1.0 g/L; ≤ 1.5 × ULN, prothrombin time (PT) ≤ 1.5 × ULN;
  11. No more than 1 month prior to screening, the subject must have participated in another interventional clinical study and recovered to a severity level of ≤ 1 for any treatment-related adverse events.

Exclusion criteria

Exclusion Criteria:

  1. History of receiving hematopoietic stem cell transplantation, adoptive cell therapy (such as CAR-T therapy), or other gene-modified cell therapies;
  2. Any active central nervous system (CNS) involvement (including symptomatic and asymptomatic), or a history of CNS disease (such as epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar disorders, or any diseases involving the CNS);
  3. Positive for surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA positivity, or subjects with HBV titers above the for the study center; positive for virus (HCV) antibody and peripheral blood HCV RNA positivity; positive for cytomegalovirus (CMV) DNA; positive for (HIV) antibody; positive for syphilis test;
  4. Any unstable systemic disease, including but not limited to unstable angina, cerebrovascular accident or (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure ( [NYHA] classification ≥ III), active bleeding, severe arrhythmias requiring drug treatment, liver, kidney, or metabolic disorders;
  5. Presence of malignant tumors other than large B-cell lymphoma, except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, localized prostate cancer, superficial bladder cancer, ductal carcinoma in situ, and other cancers with a disease-free survival of more than 5 years;
  6. Presence of gastric lymphoma, bulky disease, a history of CD19+ leukemia, or active autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, etc.);
  7. Presence of uncontrolled active infections requiring treatment (e.g., sepsis, bacteremia, fungemia, viremia) (mild urinary tract infections or upper respiratory tract infections are exceptions), with the exception of prophylactic anti-infection treatment (for bacterial, fungal, viral infections, etc.);
  8. Subjects who have received systemic treatment within 2 weeks before PBMC collection and are determined by the investigator to require long-term systemic steroid treatment during the treatment period (except for inhaled, local application, or physiological replacement doses [hydrocortisone ≤7 mg·d-1 or equivalent prednisone ≤5 mg·d-1 or dexamethasone ≤0.5 mg·d-1]);
  9. Subjects who have received anti-tumor treatment within 8 weeks or 5 half-lives (specific medications need to be assessed in detail) before PBMC collection, including chemotherapy, CD20-targeted therapy, etc.; local radiotherapy within 12 weeks;
  10. Subjects who have used granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 4 weeks before PBMC collection or within at least 5 half-lives (whichever is shorter);
  11. Subjects who have received alendronate treatment within 6 months before PBMC collection, or who have received fludarabine, cladribine, or bendamustine treatment within 3 months before PBMC collection;
  12. Subjects who have undergone major surgery within 4 weeks prior to screening (as defined by "Clinical Application Measures of Medical Technology" and "Grade 3 and 4 surgeries") or who have not fully recovered from any previous invasive procedure;
  13. Subjects who have received a within 28 days before PBMC collection;
  14. Pregnant or breastfeeding women, or those who plan to become pregnant during the treatment period or within 2 years after treatment, or male subjects whose partners plan to become pregnant within 2 years after male subject's cell injection;
  15. Subjects whom the investigator deems unsuitable to participate in this trial.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    C402-CD19-CAR

    To determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of C402-CD19-CAR cell therapy in patients with relapsed or refractory large B cell lymphoma. Dose cohorts: * Dose level 1: 0.3x105 CD19 CAR positive cells/kg body weight, subcutaneous injection * Dose level 2: 1 x105 CD19 CAR positive cells/kg body weight, subcutaneous injection * Dose level 3: 3 x105 CD19 CAR positive cells/kg body weight, subcutaneous injection

    Biological: C402-CD19-CAR

Interventions

  • BiologicalC402-CD19-CAR

    Enrolled subjects will undergo apheresis to acquire peripheral blood mononuclear cells. C402-CD19-CAR will be generated from the subject's autologous T cells modified from the apheresis product. After C402-CD19-CAR production and product release, subjects will be administered with a single dose of C402-CD19-CAR via subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. MTD (maximum tolerated dose) of C402-CD19-CAR

    To evaluate the DLT (dose limiting toxicities), attributed to C402-CD19-CAR per cohort and determine the RP2D (recommended phase 2 dose).

    Time frame: 28 days following injection

  2. AE (Adverse Event), AESI (Adverse Event of Special Interest), SAE (Severe Adverse Event)

    The incidence, severity and duration of AE, AESI and SAE as determined by NCI-CTCAE v5.0

    Time frame: up to 2 years post injection

Secondary outcomes

  1. ORR (Objective Response Rate)

    ORR and best overall response (BOR) of subjects with PR (partial response) and CR (complete response) as determined by local investigator using Lugano 2014

    Time frame: up to 2 years post injection

  2. DOR (Duration of response)

    The duration of time from record of response to first progression of disease or death as determined by Lugano 2014

    Time frame: up to 2 years post injection

  3. PFS (Progression free survival)

    The duration of time from treatment to first progression of disease as determined by Lugano 2014

    Time frame: up to 2 years post injection

  4. DCR (Disease control rate)

    The proportion of subjects with CR (complete response), PR (partial response) or SD (stable disease lasting over 6 months) to total number of patients treated as determined by local investigator using Lugano 2014

    Time frame: up to 2 years post injection

  5. OS (Overall Survival)

    The time from the start of treatment to the occurrence of death due to any cause

    Time frame: up to 15 years post injection

  6. PK (Pharmacokinetics): AUCinf

    Calculate AUCinf: area under the blood concentration-time curve extrapolated to infinity

    Time frame: up to 2 years post injection

  7. PK: AUC(0-t)

    calculate AUC(0-t): the AUC from time 0 to the last measurable concentration that represents the observed exposure to a drug

    Time frame: up to 2 years post injection

  8. PK: AUC0-28d

    calculate AUC0-28d: the area under the concentration-time curve from day 0 to day 28

    Time frame: up to 2 years post injection

  9. PK: AUC0-90d

    Calculate AUC0-90d: the area under the concentration-time curve from day 0 to day 90

    Time frame: up to 2 years post injection

  10. PK: Cmax

    Calculate Cmax: the highest concentration of the drug in the blood

    Time frame: up to 2 years post injection

  11. PK: half-life

    Calculate half-life: the time it takes for the amount of the drug's active substance in your body to reduce by half

    Time frame: up to 2 years post injection

  12. PK: Tmax

    Calculate Tmax: the time it takes for the drug to reach the maximum concentration after administration of a drug that needs to be absorbed

    Time frame: up to 2 years post injection

  13. PK: MRT

    Calculate MRT (Mean Residence Time): the average time a molecule spends in a system before being removed)

    Time frame: up to 2 years post injection

  14. Concentration of cytokines

    Test serum concentration of IL-2、IL-4、IL-6、IL-10、IFN-γ、TNF-α before and post C402-CD19-CAR treatment

    Time frame: up to 2 years post injection

  15. Concentration of Anti-Drug Antibody

    Test antibodies that form in response to the administration of C402-CD19-CAR

    Time frame: up to 2 years post injection

Other outcomes

  1. Correlation between PK, cytokine concentration and efficacy

    Calculate the correlation between PK data, cytokine concentration with efficacy parameters (PFS, OS, ORR, DCR, DOR)

    Time frame: up to 2 years post injection

  2. B cell count

    Test B cell count and the subsets percentage in blood before and post C402-CD19-CAR treatment

    Time frame: up to 2 years post injection

  3. RCL (replication-competent lentivirus) test

    Test VSVG copies/μg gDNA in blood after treatment

    Time frame: up to 15 years post injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Liu W, Liu J, Song Y, Zeng X, Wang X, Mi L, Cai C, Wang L, Ma J, Zhu J; Union for China Leukemia Investigators of the Chinese Society of Clinical Oncology; Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019 Nov 19;12(1):115. doi: 10.1186/s13045-019-0785-7. PubMed 31744509 ↗
  • Liu W, Liu J, Song Y, Wang X, Mi L, Cai C, Zhao D, Wang L, Ma J, Zhu J. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY). 2022 Apr 10;14(7):3175-3190. doi: 10.18632/aging.204006. Epub 2022 Apr 10. PubMed 35398840 ↗
  • Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, McBride A, Iftikhar A, Anwer F. A Review of Autologous Stem Cell Transplantation in Lymphoma. Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. doi: 10.1007/s11899-017-0382-1. PubMed 28478586 ↗
  • Li X, Ding Y, Zi M, Sun L, Zhang W, Chen S, Xu Y. CD19, from bench to bedside. Immunol Lett. 2017 Mar;183:86-95. doi: 10.1016/j.imlet.2017.01.010. Epub 2017 Jan 30. PubMed 28153605 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2029, 49 months after the start.

Of 91 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 49 months is close to that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 17, 2025
StartActual
Mar 25, 2025
Primary completionEst.
Apr 28, 2029
CompletionEst.
Sep 18, 2029
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830031
Lead sponsor
Shanghai Exuma Biotechnology Ltd.
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Mar 25, 2025
Primary completion
Apr 28, 2029 (estimated)
Completion
Sep 18, 2029 (estimated)
Last update
Sep 11, 2026

Study contacts

Xue Zhang, Master
Contact
xue.zhang2@kuntuo.com
0086-18020181261
Yansong Li, Master
Contact
yansong.li@kuntuo.com
0086-15618427667
Liang Huang, MD
principal investigator · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion